Multiscale computational insights into 5-Fluorouracil delivery via Zeolite Imidazole Frameworks (ZIFs)

Abstract

Zeolitic Imidazolate Frameworks (ZIFs) are considered as potential nanocarriers in biomedical applications such as storage and transportation of drugs, due to their low toxicity, high internal load and controlled release. In this work, the adsorption of the anticancer drug 5-Fluorouracil (5-FU) in selected ZIFs is studied by employing a multiscale computational scheme that includes semi-empirical computational techniques, Grand Canonical Monte Carlo (GCMC) and Molecular Dynamics simulations. Our investigation is based on ZIF-8 which is characterized by pH-sensitive controlled drug release. In order to improve the capacity and the drug interaction with the framework we expanded the parent ZIF-8, by replacing each imidazole linker with 3-(1H-pyrrol-3-yl)-pyridine. 5-FU shows enhanced binding affinity (34 kcal/mol) in modified ZIF with respect to the parent ZIF-8 (12 kcal/mol) (PM7). Moreover, GCMC simulations were employed to determine the loading of 5-FU in both ZIF compounds under different thermodynamic conditions and over a wide range of pressures, where it is revealed that the loading for the modified ZIF (2311 mg/g) is four times higher than the loading for ZIF-8 (560 mg/g). Moreover, Molecular Dynamics simulations offer a detailed comparison between the two ZIF materials in aqueous systems and provide deeper insight into their drug-material interactions.

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Paper
Submitted
25 Feb 2025
Accepted
06 Jun 2025
First published
25 Jun 2025
This article is Open Access
Creative Commons BY license

RSC Pharm., 2025, Accepted Manuscript

Multiscale computational insights into 5-Fluorouracil delivery via Zeolite Imidazole Frameworks (ZIFs)

M. Vlachos, G. Turtú, M. Severi, E. Tyllianakis, E. Klontzas, F. Zerbetto and G. Froudakis, RSC Pharm., 2025, Accepted Manuscript , DOI: 10.1039/D5PM00058K

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements